JEJustin G. English

Justin G. English

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Justin G. English has a total of 120 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Distinct activation mechanisms underlie ligand efficacy at a GPCR

    by Matthew K. Howard, Eve J. Fine, Karthik Srinivasan, Daniel D. Richman, Jerome Freudenberg, Zara Weinberg, Jingyou Rao, Ziyue Zou, Christian Macdonald, Patrick Rockefeller Grimes, et al.

    Ligands that bind to the same G protein-coupled receptor (GPCR) can produce widely different levels of signaling. These differences in efficacy are central to pharmacology, yet how a receptor sequence determines signaling level remains incompletely understood. Here we develop a deep mutational pharmacology approach to measure how each residue in the µ-opioid receptor (µOR) shapes responses to 15 opioids, yielding ∼400,000 measurements of variant effects on signaling and expression, including full concentration-response series for three agonists. Mutational effects on potency are strongest near the orthosteric pocket, whereas effects on efficacy extend through the transmembrane core and intracellular face. Ligands share many functional determinants, but sensitivity to mutation differs with efficacy. As efficacy decreases, the residues required for signaling shift from the binding pocket towards the intracellular face; partial agonists therefore depend on residues that are dispensable for full agonists. Mutations can broadly increase receptor responses, allowing antagonists such as naloxone to produce signaling comparable to a full agonist and increasing the efficacy of partial agonist ligands. Combined mutations can also reorder the relative efficacies of ligands, showing that sequence changes reshape pharmacological differences rather than simply increasing or decreasing all responses together. These findings support a model in which ligands of different efficacy activate the receptor through distinct allosteric mechanisms which are determined by residues distributed across the receptor. Mapping these contributions across diverse ligands with deep mutational pharmacology provides a way to understand how one receptor converts molecular recognition into a range of signaling outputs.


  • Open Access

    Protease-activated receptor 1 as an endogenous model of peptidergic Gαq-Gα12-biased G protein signaling

    by Braden S. Fallon, Robert A. Campbell, Justin G. English

    Introduction: G protein-coupled receptors (GPCRs) are the most widely targeted class of signaling proteins, comprising ∼30% of FDA-approved drugs. Their therapeutic potential arises from their ability to translate diverse extracellular cues into intracellular signals via G proteins, arrestins, and other effectors. This signaling versatility creates opportunities for functional selectivity, where ligands preferentially engage particular pathways. However, few endogenous receptor systems display well-defined ligand-dependent divergence across multiple signaling levels. Protease-activated receptor 1 (PAR1) is a candidate model. Thrombin canonically cleaves PAR1 at Arg41, whereas activated protein C (aPC) has been reported to cleave PAR1 at Arg46 in endothelial and co-receptor-supported settings, creating distinct tethered peptide ligands. Thrombin cleavage drives canonical Gαq- and Gα12/13-dependent prothrombotic and barrier-disruptive signaling, whereas aPC cleavage has been associated with anticoagulant, cytoprotective, and anti-inflammatory signaling. However, PAR1’s transducer-wide coupling profile, transcriptional consequences, and physiological outputs remain incompletely characterized. Methods: We integrated transducer-wide biosensor assays (TRUPATH, TGFα shedding, PRESTO-Tango), analysis of a PAR1 ± thrombin TRE-MPRA dataset followed by targeted TRE dual-luciferase validation, and platelet activation and calcium flux studies in primary human platelets to define how protease identity reshapes signaling from proximal transducer engagement to physiological output. Results: Thrombin produced robust PAR1 coupling to Gαq and Gα12, whereas aPC produced detectable coupling only to Gα12. Neither protease generated detectable β-arrestin-2 recruitment in PRESTO-Tango. Both proteases supported dose-dependent TGFα shedding that was insensitive to FR900359. A PAR1 ± thrombin TRE-MPRA dataset identified thrombin-responsive transcriptional response elements and nominated NFκB1 and THRB for targeted follow-up. Luciferase assays showed NFκB1 was thrombin-induced and FR900359-sensitive, whereas THRB was induced by both thrombin and aPC and was FR900359-insensitive. In primary human platelets, thrombin, but not aPC, induced P-selectin expression and a calcium response. Thrombin responses were suppressed by FR900359, supporting a requirement for Gαq in these platelet activation markers. Discussion: Together, these findings support PAR1 as an endogenous model of protease-dependent functional selectivity that, in our heterologous assay systems, separates signaling along a Gαq-versus-Gα12 axis, thus providing a framework for future technologies, such as high-throughput tethered-peptide evolution platforms, to understand the principles of G protein selectivity across GPCRs.

  • Open Access

    Protease-Activated Receptor 1 as an Endogenous Model of Peptidergic Gαq-Gα12-Biased G Protein Signaling

    by Braden S. Fallon, Robert A. Campbell, Justin G. English

    G protein-coupled receptors (GPCRs) are the most widely targeted class of signaling proteins, comprising ~30% of FDA-approved drugs. Their therapeutic potential arises from their ability to translate diverse extracellular cues into intracellular signals via G proteins, arrestins, and other effectors. This signaling versatility creates opportunities for functional selectivity, where ligands preferentially engage particular pathways. However, few endogenous receptor systems display well-defined ligand-dependent divergence across multiple signaling levels. Protease-activated receptor 1 (PAR1) is a candidate model. Thrombin canonically cleaves PAR1 at Arg41, whereas activated protein C (aPC) has been reported to cleave PAR1 at Arg46 in endothelial and co-receptor-supported settings, creating distinct tethered peptide ligands. Thrombin cleavage drives canonical Gαq- and Gα12/13-dependent prothrombotic and barrier-disruptive signaling, whereas aPC cleavage has been associated with anticoagulant, cytoprotective, and anti-inflammatory signaling. However, PAR1’s transducer-wide coupling profile, transcriptional consequences, and physiological outputs remain incompletely characterized. We integrated transducer-wide biosensor assays (TRUPATH, TGFα shedding, PRESTO-Tango), analysis of a PAR1 ± thrombin TRE-MPRA dataset followed by targeted TRE dual-luciferase validation, and platelet activation and calcium flux studies in primary human platelets to define how protease identity reshapes signaling from proximal transducer engagement to physiological output. Thrombin produced robust PAR1 coupling to Gαq and Gα12, whereas aPC produced detectable coupling only to Gα12. Neither protease generated detectable β-arrestin-2 recruitment in PRESTO-Tango. Both proteases supported dose-dependent TGFα shedding that was insensitive to FR900359. A PAR1 ± thrombin TRE-MPRA dataset identified thrombin-responsive transcriptional response elements and nominated NFκB1 and THRB for targeted follow-up. Luciferase assays showed NFκB1 was thrombin-induced and FR900359-sensitive, whereas THRB was induced by both thrombin and aPC and was FR900359-insensitive. In primary human platelets, thrombin, but not aPC, induced P-selectin expression and a calcium response. Thrombin responses were suppressed by FR900359, supporting a requirement for Gαq in these platelet activation markers. Together, these findings support PAR1 as an endogenous model of protease-dependent functional selectivity that, in our heterologous assay systems, separates signaling along a Gαq-versus-Gα12 axis, thus providing a framework for future technologies, such as high-throughput tethered-peptide evolution platforms, to understand the principles of G protein selectivity across GPCRs.

  • ConSeqUMI, an error-free nanopore sequencing pipeline to identify and extract individual nucleic acid molecules from heterogeneous samples

    by Adam M Zahm, Caleb W Cranney, Alexa N Gormick, Kathleen E Rondem, Benjamin Schmitz, Samuel R Himes, Justin G English

    Nanopore sequencing has revolutionized genetic analysis by offering linkage information across megabase-scale genomes. However, the high intrinsic error rate of nanopore sequencing impedes the analysis of complex heterogeneous samples, such as viruses, bacteria, complex libraries, and edited cell lines. Achieving high accuracy in single-molecule sequence identification would significantly advance the study of diverse genomic populations, where clonal isolation is traditionally employed for complete genomic frequency analysis. Here, we introduce ConSeqUMI, an innovative experimental and analytical pipeline designed to address long-read sequencing error rates using unique molecular indices for precise consensus sequence determination. ConSeqUMI processes nanopore sequencing data without the need for reference sequences, enabling accurate assembly of individual molecular sequences from complex mixtures. We establish robust benchmarking criteria for this platform’s performance and demonstrate its utility across diverse experimental contexts, including mixed plasmid pools, recombinant adeno-associated virus genome integrity, and CRISPR/Cas9-induced genomic alterations. Furthermore, ConSeqUMI enables detailed profiling of human pathogenic infections, as shown by our analysis of severe acute respiratory syndrome coronavirus 2 spike protein variants, revealing substantial intra-patient genetic heterogeneity. Lastly, we demonstrate how individual clonal isolates can be extracted directly from sequencing libraries at low cost, allowing for post-sequencing identification and validation of observed variants. Our findings highlight the robustness of ConSeqUMI in processing sequencing data from UMI-labeled molecules, offering a critical tool for advancing genomic research.


  • High-Throughput Characterization of Tetracycline Repressor Function on Tetracycline Operator 2 Variants

    by Alexa N. Gormick, Adam M. Zahm, Samuel R. Himes, Kathleen E. Rondem, Justin G. English

    Chemogenetic regulators of transgene activity, such as the tetracycline-inducible system derived from the tetracycline resistance operon of the bacterial transposon Tn10, are critical and widely used systems in cellular engineering. The tetracycline-inducible system is prized for its selectivity, high affinity, inducibility, reversibility, and differential control of gene transcription. However, its optimization for binary on/off expression limits its application in systems biology and the modeling and construction of complex regulatory systems with intricate input/output paradigms. To overcome this limitation, we developed a high-throughput reporter system to investigate a saturated mutagenesis library of tetracycline resistance operator variants. Using this system, we mapped the functional interactions of Tet repressor DNA binding protein at single-nucleotide resolution in mammalian cells. Our comprehensive screen revealed a spectrum of variant effects, ranging from a nearly complete loss of repression to levels indistinguishable from the natural operator, validated through orthogonal assays. This comprehensive characterization of the sequence-specificity of a tetracycline resistance operator facilitates the construction of variably suppressive, inducible systems for dynamic and modular control over gene expression in mammalian cell culture.


  • Open Access

    ConSeqUMI, an error-free nanopore sequencing pipeline to identify and extract individual nucleic acid molecules from heterogeneous samples

    by Adam M. Zahm, Caleb W. Cranney, Alexa N. Gormick, Kathleen E. Rondem, Benjamin Schmitz, Samuel R. Himes, Justin G. English

    Nanopore sequencing has revolutionized genetic analysis by offering linkage information across megabase-scale genomes. However, the high intrinsic error rate of nanopore sequencing impedes the analysis of complex heterogeneous samples, such as viruses, bacteria, complex libraries, and edited cell lines. Achieving high accuracy in single-molecule sequence identification would significantly advance the study of diverse genomic populations, where clonal isolation is traditionally employed for complete genomic frequency analysis. Here, we introduce ConSeqUMI, an innovative experimental and analytical pipeline designed to address long-read sequencing error rates using unique molecular indices for precise consensus sequence determination. ConSeqUMI processes nanopore sequencing data without the need for reference sequences, enabling accurate assembly of individual molecular sequences from complex mixtures. We establish robust benchmarking criteria for this platform’s performance and demonstrate its utility across diverse experimental contexts, including mixed plasmid pools, recombinant adeno-associated virus genome integrity, and CRISPR/Cas9-induced genomic alterations. Furthermore, ConSeqUMI enables detailed profiling of human pathogenic infections, as shown by our analysis of SARS-CoV-2 spike protein variants, revealing substantial intra-patient genetic heterogeneity. Lastly, we demonstrate how individual clonal isolates can be extracted directly from sequencing libraries at low cost, allowing for post-sequencing identification and validation of observed variants. Our findings highlight the robustness of ConSeqUMI in processing sequencing data from UMI-labeled molecules, offering a critical tool for advancing genomic research. GRAPHICAL ABSTRACT


  • Biased Signaling in G Protein-Coupled Receptors: Understanding the Biological Relevance and Tools for Probing Functionally Selective Ligands

    by Braden S. Fallon, Kathleen E. Rondem, Elizabeth J. Mumby, Justin G. English

    Biased signaling has transformed pharmacology by revealing that receptors, particularly G protein-coupled receptors (GPCRs), can activate specific intracellular pathways selectively rather than uniformly. This discovery enables the development of targeted therapeutics that minimize side effects by precisely modulating receptor activity. Functionally selective ligands, which preferentially activate distinct signaling branches, have become essential tools for exploring receptor mechanisms and uncovering the complexities of GPCR signaling. These ligands help clarify receptor function in various physiological and pathological contexts, offering profound implications for therapeutic innovation. GPCRs, which mediate a wide range of cellular responses through coupling to G proteins and arrestins, are key pharmacological targets, with nearly a third of FDA-approved drugs acting on them. Recent advancements in biosensor development, multiplex assay platforms, and deep mutational scanning methods are improving our ability to define GPCR signaling, allowing for a better understanding of biased signaling pathways.


  • Open Access

    A massively parallel reporter assay library to screen short synthetic promoters in mammalian cells

    by Adam M. Zahm, William S. Owens, Samuel R. Himes, Braden S. Fallon, Kathleen E. Rondem, Alexa N. Gormick, Joshua S. Bloom, Sriram Kosuri, Henry Chan, Justin G. English

    Cellular responses to stimuli underpin discoveries in drug development, synthetic biology, and general life sciences. We introduce a library comprising 6144 synthetic promoters, each shorter than 250 bp, designed as transcriptional readouts of cellular stimulus responses in massively parallel reporter assay format. This library facilitates precise detection and amplification of transcriptional activity from our promoters, enabling the systematic development of tunable reporters with dynamic ranges of 50−100 fold. Our library proved functional in numerous cell lines and responsive to a variety of stimuli, including metabolites, mitogens, toxins, and pharmaceutical agents, generating robust and scalable reporters effective in screening assays, biomarkers, and synthetic circuits attuned to endogenous cellular activities. Particularly valuable in therapeutic development, our library excels in capturing candidate reporters to signals mediated by drug targets, a feature we illustrate across nine diverse G-protein coupled receptors (GPCRs), critical targets in drug development. We detail how this tool isolates and defines discrete signaling pathways associated with specific GPCRs, elucidating their transcriptional signatures. With its ease of implementation, broad utility, publicly available data, and comprehensive documentation, our library will be beneficial in synthetic biology, cellular engineering, ligand exploration, and drug development.


  • Open Access

    Molecular basis of proton-sensing by G protein-coupled receptors

    by Matthew K. Howard, Nicholas Hoppe, Xi-Ping Huang, Christian B. Macdonald, Eshan Mehrota, Patrick Rockefeller Grimes, Adam Zahm, Donovan D. Trinidad, Justin English, Willow Coyote-Maestas, et al.

    Three proton-sensing G protein-coupled receptors (GPCRs), GPR4, GPR65, and GPR68, respond to changes in extracellular pH to regulate diverse physiology and are implicated in a wide range of diseases. A central challenge in determining how protons activate these receptors is identifying the set of residues that bind protons. Here, we determine structures of each receptor to understand the spatial arrangement of putative proton sensing residues in the active state. With a newly developed deep mutational scanning approach, we determined the functional importance of every residue in proton activation for GPR68 by generating ∼9,500 mutants and measuring effects on signaling and surface expression. This unbiased screen revealed that, unlike other proton-sensitive cell surface channels and receptors, no single site is critical for proton recognition in GPR68. Instead, a network of titratable residues extend from the extracellular surface to the transmembrane region and converge on canonical class A GPCR activation motifs to activate proton-sensing GPCRs. More broadly, our approach integrating structure and unbiased functional interrogation defines a new framework for understanding the rich complexity of GPCR signaling. One-sentence summary The protonation networks governing activation of human pH-sensing GPCRs are uncovered by integrative cryo-EM and deep mutational scanning.


  • Measuring Ligand‐bound Protein Complexes with Proximity Labeling: A Practical Guide

    by Pavitra Goyal, Andrew J. Tao, Elizabeth J. Mumby, Justin G. English, Fleur M. Ferguson

    Identifying the drug‐target interactome of small molecule therapeutics is essential for understanding the full pharmacological effects of a compound. These therapies often induce changes within the cellular proteome, leading to unexpected consequences such as changes in the targets complexation state or off‐target interactions between the compound and additional proteins. Currently, unbiased target‐ID approaches are being used to embark on this task. Here we provide an overview of the strengths and limitations of these methods, and a practical step‐by‐step protocol for using the BioTAC system to assist with drug target and interactome ID.